PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFX) was the target of a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 78,499 shares, a drop of 64.6% from the February 12th total of 221,954 shares. Currently, 29.7% of the company’s stock are short sold. Based on an average daily volume of 66,985 shares, the days-to-cover ratio is presently 1.2 days. Based on an average daily volume of 66,985 shares, the days-to-cover ratio is presently 1.2 days. Currently, 29.7% of the company’s stock are short sold.

PainReform Stock Performance

NASDAQ:PRFX opened at $2.67 on Wednesday. The company has a market capitalization of $1.07 million, a P/E ratio of 0.00 and a beta of 0.55. The stock’s 50 day moving average price is $3.49 and its 200 day moving average price is $5.04. PainReform has a 52 week low of $2.50 and a 52 week high of $17.95.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PainReform in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.